RLMD Relmada Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RLMD

Price (delayed)

$3.68

Market cap

$111.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.28

Enterprise value

$106.95M

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed ...

Highlights
The EPS has grown by 38% YoY and by 11% from the previous quarter
Relmada Therapeutics's net income has increased by 37% YoY and by 11% QoQ
RLMD's equity is down by 39% YoY and by 15% from the previous quarter
The quick ratio has contracted by 37% from the previous quarter and by 34% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.relmada.com
Peers: CYTK

Key stats

What are the main financial stats of RLMD
Market
Shares outstanding
30.17M
Market cap
$111.04M
Enterprise value
$106.95M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.3
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$98.79M
EBITDA
-$98.79M
Free cash flow
-$51.66M
Per share
EPS
-$3.28
Free cash flow per share
-$1.72
Book value per share
$2.84
Revenue per share
$0
TBVPS
$3.24
Balance sheet
Total assets
$97.55M
Total liabilities
$12.19M
Debt
$0
Equity
$85.36M
Working capital
$85.31M
Liquidity
Debt to equity
0
Current ratio
8
Quick ratio
7.9
Net debt/EBITDA
0.04
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-85.1%
Return on equity
-93.4%
Return on invested capital
-107.2%
Return on capital employed
-115.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RLMD stock price

How has the Relmada Therapeutics stock price performed over time
Intraday
-1.08%
1 week
-3.92%
1 month
-21.87%
1 year
35.29%
YTD
-11.11%
QTD
-20.86%

Financial performance

How have Relmada Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$103.7M
Net income
-$98.79M
Gross margin
N/A
Net margin
N/A
Relmada Therapeutics's net income has increased by 37% YoY and by 11% QoQ
Relmada Therapeutics's operating income has increased by 36% YoY and by 10% from the previous quarter

Growth

What is Relmada Therapeutics's growth rate over time

Valuation

What is Relmada Therapeutics stock price valuation
P/E
N/A
P/B
1.3
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 38% YoY and by 11% from the previous quarter
The P/B is 71% less than the 5-year quarterly average of 4.5 but 44% more than the last 4 quarters average of 0.9
RLMD's equity is down by 39% YoY and by 15% from the previous quarter

Efficiency

How efficient is Relmada Therapeutics business performance
The ROA has declined by 6% year-on-year
Relmada Therapeutics's return on equity has decreased by 6% YoY

Dividends

What is RLMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLMD.

Financial health

How did Relmada Therapeutics financials performed over time
RLMD's total liabilities is up by 45% QoQ but it is down by 2.2% YoY
The company's current ratio fell by 38% QoQ and by 35% YoY
RLMD's debt is 100% smaller than its equity
RLMD's equity is down by 39% YoY and by 15% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.